Replies to post #236513 on Biotech Values

[DewDiligence]

MYOV claims that ~75% of Orgovyx patients will have an OOP cost of $10/month or less (https://investors.myovant.com/static-files/9261c91d-cb2c-4768-a891-aca163308188 slide #26).

[DewDiligence]

Curious that AbbVie did not pursue this indication for elagolix.

I was hoping you could explain that!